Cite
HARVARD Citation
Jones, R. et al. (2020). Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial. Lancet oncology. 21 (3), pp. 345-357. [Online].